News stories about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive on Sunday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.396835441636 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
A number of research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a research report on Wednesday, November 22nd. Cowen reiterated a “buy” rating on shares of Alimera Sciences in a research report on Thursday, November 2nd. Zacks Investment Research upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Finally, ValuEngine upgraded Alimera Sciences from a “strong sell” rating to a “sell” rating in a research report on Friday, October 20th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.38.
Alimera Sciences (NASDAQ:ALIM) opened at $1.30 on Friday. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65. Alimera Sciences has a 12-month low of $1.06 and a 12-month high of $1.72.
COPYRIGHT VIOLATION WARNING: “Alimera Sciences (ALIM) Given Media Sentiment Rating of 0.15” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/10/alimera-sciences-alim-given-media-sentiment-rating-of-0-15.html.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.